Featuring an interview with Dr Scott Kopetz, including the following topics:

• Circulating tumor DNA (ctDNA)-based molecular residual disease (MRD) and survival among patients with resectable colorectal cancer (CRC) in the CIRCULATE-Japan GALAXY trial (0:00)
• ctDNA for detection of MRD in patients with CRC in the BESPOKE CRC and INTERCEPT trials (3:11)
• Clinical utility of including ctDNA monitoring in standard CRC surveillance (11:11)
• ctDNA analysis guiding adjuvant therapy for CRC in the DYNAMIC and CIRCULATE-North America trials (15:52)

CME information and select publications

Featuring perspectives from Dr Harry Paul Erba, Dr Amir Fathi, Dr Tara L Lin, Dr Alexander Perl and Dr Eytan M Stein, including the following topics:

• Introduction (0:00)
• Up-Front Therapy for Older Patients with Acute Myeloid Leukemia (AML) — Dr Lin (1:46)
• Selection of Therapy for Younger Patients with AML without a Targetable Mutation; Promising Investigational Strategies — Dr Perl (25:38)
• Role of FLT3 Inhibitors in AML Management — Dr Erba (48:27)
• Incorporation of IDH Inhibitors into the Care of Patients with AML — Dr Fathi (1:10:28)
• Current and Future Role of Menin Inhibitors in the Treatment of AML — Dr Stein (1:37:29)

CME information and select publications

Featuring perspectives from Dr Lisa A Carey and Dr Rita Nanda, including the following topics:

• Overview: Molecular basis of antibody-drug conjugate (ADC) toxicities — Sequencing of ADCs and mechanisms of resistance (0:00)
• Case: A woman in her late 60s with localized triple-negative breast cancer develops myocarditis during neoadjuvant therapy with chemotherapy/pembrolizumab — Richard Zelkowitz, MD (8:22)
• Case: A woman in her mid 70s with recurrent ER-negative, HER2-low, PD-L1-positive metastatic breast cancer (mBC) who experiences disease progression on nab paclitaxel/atezolizumab responds to sacituzumab govitecan — Ranju Gupta, MD (26:43)
• Case: A woman in her early 80s with recurrent ER-positive, HER2-low (IHC 1+) mBC experiences disease progression on trastuzumab deruxtecan (T-DXd), then receives datopotamab deruxtecan and develops pulmonary symptoms — Laila Agrawal, MD (32:11)
• Data Review: T-DXd (37:51)
• Case: A woman in her early 70s with recurrent ER-positive, HER2-low (IHC 1+) mBC, including bladder metastases, experiences disease progression after palbociclib/letrozole, then capivasertib/fulvestrant, then nab paclitaxel — Justin Favaro, MD, PhD (44:02)
• Case: A woman in her late 70s with ER-positive, HER2-low mBC who experiences disease progression after 1 year of ribociclib/letrozole receives sacituzumab govitecan — Erik Rupard, MD (55:19)

CME information and select publications

Featuring perspectives from Dr Yelena Y Janjigian, including the following topics:

• Introduction (0:00)
• Case: A man in his early 60s with a history of Barrett's esophagus presents with HER2-positive metastatic esophageal adenocarcinoma and a PD-L1 combined positive score (CPS) of 3 — Jennifer Yannucci, MD (10:20)
• Case: A man in his early 60s with multiregimen-recurrent HER2-positive gastroesophageal junction (GEJ) adenocarcinoma (claudin 18.2-positive, PD-L1 CPS 0) — Neil Morganstein, MD (14:53)
• Case: A woman in her early 80s with dementia and newly diagnosed mismatch repair-deficient, PD-L1-positive metastatic GEJ adenocarcinoma — Brian P Mulherin, MD (25:55)
• Case: A man in his mid 60s with localized HER2-negative GEJ cancer (PD-L1 CPS 2, claudin 18.2-positive) and residual disease after receiving neoadjuvant chemoradiation therapy and undergoing surgery — Stephen "Fred" Divers, MD (32:18)
• Case: A man in his early 80s with metastatic recurrence of esophageal adenocarcinoma and a PD-L1 total proportion score of 75% 2 years after resection of localized disease — Susmitha Apuri, MD (40:28)
• Case: A man in his mid 70s with claudin 18.2-positive metastatic esophageal adenocarcinoma who develops progressive toxicities with FOLFOX and zolbetuximab — Sean Warsch, MD (52:54)

CME information and select publications

Featuring perspectives from Dr Terence Friedlander and Dr Rana R McKay, including the following topics:

• Introduction (0:00)
• Prostate Cancer (1:44)
• Urothelial Bladder Cancer (29:18)

CME information and select publications

Featuring perspectives from Dr Luis Paz-Ares and Dr Misty Dawn Shields, including the following topics:

• Introduction: Tail on the Curve? (0:00)
• First-Line Chemoimmunotherapy (10:45)
• Maintenance Lurbinectedin (28:42)
• Second-Line Treatment, Tarlatamab (45:35)
• Ongoing Research (53:20)

CME information and select publications

Featuring perspectives from Dr Manish A Shah, moderated by Dr Stephen "Fred" Divers, including the following topics:

• Highlights and Principles of Management of Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma — Dr Shah (0:00)
• Case: A man in his early 50s with microsatellite instability-high localized esophageal adenocarcinoma — Dr Mulherin (15:24)
• Case: A woman in her late 60s with HER2-positive (IHC 3+) and HER2 TKD-mutant metastatic esophageal adenocarcinoma — Dr Warsch (25:34)
• Case: A woman in her early 70s with HER2-positive (IHC 3+), PD-L1-negative, CLDN18.2-negative metastatic gastric cancer — Dr Mulherin (28:15)
• Case: A woman in her early 70s with metastatic gastroesophageal junction adenocarcinoma (PD-L1 CPS 15) who begins treatment with FOLFOX/nivolumab and subsequently is found to have CLDN18.2 overexpression — Dr Lamar (35:23)
• Case: A man in his mid 40s with CLDN18.2-positive metastatic esophageal adenocarcinoma (PD-L1 10%) who receives mFOLFOX6 and zolbetuximab — Dr Yannucci (42:54)

CE information and select publications

Featuring perspectives from Dr Gottfried E Konecny, moderated by Dr Stephen "Fred" Divers, including the following topics:

• Updates in Ovarian Cancer (OC) 2025 — Dr Konecny (0:00)
• Case: A woman in her mid 50s with ovarian cancer and a PALB2 germline mutation — Dr Mulherin (17:15)
• Case: A woman in her early 60s with Stage IVB fallopian tube carcinoma and a BRCA2 germline mutation — Dr Yannucci (26:27)
• Case: A woman in her mid 60s with OC and a BRCA2 somatic mutation who develops cytopenias on maintenance olaparib — Dr Lamar (35:47)
• Case: A woman in her early 70s with HER2 IHC 2+, ER-expressing, FOLR1-positive OC — Dr Warsch (42:54)

CE information and select publications